The Department of Health of the Hong Kong Special Administrative Region (HKSAR) Government announced on the 22nd that the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute, established and wholly owned by the HKSAR Government, officially launched the Guangdong-Hong Kong-Macao Greater Bay Area Clinical Trial Collaboration Platform.
As introduced, the Guangdong-Hong Kong-Macao Greater Bay Area Clinical Trial Collaboration Platform is a unified service portal co-established under the “One Institute, One Center” framework. It aims to integrate clinical trial resources across the Greater Bay Area and provide a one-stop service entry for global biopharmaceutical enterprises, R&D institutions and researchers, with a key focus on orphan drugs, high-end oncology drugs, as well as advanced therapy products such as cell and gene therapies.
On the same day, the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute officially set up the Real-World Study and Application Center. According to the introduction, this center will enhance the access and application of health and medical databases, and integrate real-world data generated under the “Hong Kong-Macao Medicine and Medical Devices Connect” policy. The initiative will support the registration applications of innovative drugs and medical devices in Hong Kong, the Chinese mainland and overseas markets, accelerating the R&D, approval and market launch of such products. As of December 10 this year, a total of 71 designated mainland medical institutions under the “Hong Kong-Macao Medicine and Medical Devices Connect” scheme have introduced 140 types of drugs and medical devices already marketed in Hong Kong and Macao, including 63 pharmaceutical products and 77 medical devices, benefiting over 17,000 patients.
On September 9 this year, the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute signed a tripartite cooperation memorandum with the Li Ka Shing Faculty of Medicine of the University of Hong Kong and international biopharmaceutical company GlaxoSmithKline, launching the institute’s first real-world data research project.
It is understood that the institute will better integrate the complete biopharmaceutical R&D and technology industry chain of the Greater Bay Area, make good use of the preferential national policies for Hong Kong, and give full play to Hong Kong’s role as a “super-connector” that “backs onto the motherland and connects the world”. It will also promote the Hetao Area to become a window for the “bringing in” and “going out” of innovative biopharmaceutical achievements transformation, accelerate access to advanced diagnosis and treatment for patients in the Greater Bay Area, and foster new productive forces.
